Efzofitimod

Atyr Pharma's efzofitimod, a first-in-class immunomodulating therapy, continues in Phase 3 for pulmonary sarcoidosis after a positive safety review. The therapy aims to reduce inflammation and improve lung function, with previous trials showing reduced corticosteroid need and relapse rates. The ongoing EFZO-FIT study, fully enrolled with 268 participants, is expected to conclude in 2025.

aTyr Pharma's CEO, Sanjay S. Shukla, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, in San Francisco. The presentation will be available via webcast on the company's website. aTyr focuses on tRNA synthetase biology for therapies targeting fibrosis and inflammation, with efzofitimod as its lead candidate for interstitial lung disease.

aTyr Pharma appoints Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, currently Chief Commercial Officer at Neurocrine Biosciences, brings over 30 years of pharmaceutical commercial experience. aTyr is a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation therapies.

An independent DSMB reviewed the Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, involving 268 patients, and recommended continuing without modifications. The study evaluates efzofitimod's efficacy and safety, aiming to reduce steroid use and improve lung function and symptoms.

aTyr Pharma's CEO, Sanjay S. Shukla, will present at the 17th Annual LD Micro Main Event on Oct 29, 2024, in Los Angeles. The event features 150 companies and includes private investor meetings. aTyr focuses on tRNA synthetase biology for fibrosis and inflammation therapies, with lead candidate efzofitimod for interstitial lung disease.

aTyr Pharma advances clinical programs with Efzo in pulmonary sarcoidosis and SSc-ILD trials, attracting investor interest. The company faces risks from trial outcomes and regulatory approvals, but successful results could significantly boost market position. Analysts maintain a positive outlook with a $16.00 price target, highlighting potential volatility and upside.

In 2023, systemic sclerosis market size was USD 1,850M in 7MM, with the US leading. Italy had the largest market in EU4 and UK. The US also had the highest diagnosed cases. Treatments like OFEV and ACTEMRA are approved, but Rituximab showed significant improvements. Emerging therapies, including CAR-T cell therapies, are in development, promising future growth. The disease's severity varies by organ involvement, with lung disease being a major concern.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.

DelveInsight's report forecasts an increase in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) cases by 2034, highlighting the UK's highest prevalence. With 83% of 64,000 cases diagnosed in 2023, there's a call for better screening. Females are more affected, and severe cases account for 30%. Emerging therapies like Mycophenolate mofetil and Nintedanib are promising, with companies like Genentech and Boehringer Ingelheim leading the market.